Publication
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (9)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 9
- cancerCutaneous Melanomacivic_curation1.00
- drugMEK Inhibitor REC-4881civic_curation1.00
- drugTrametinibcivic_curation1.00
- drugVemurafenibcivic_curation1.00
- geneBRAFcivic_curation1.00
- variantBRAF K601Ecivic_curation1.00
- variantBRAF L597Qcivic_curation1.00
- variantBRAF L597Rcivic_curation1.00
- variantBRAF L597Scivic_curation1.00
Curated evidence
Evidence citing this paper (5)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 22798288
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF K601E1 | ||||||||
| Trametinib + VemurafenibSubstitutes | Cutaneous MelanomaALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1462Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutant–expressing cells led… (full text at CIViC) PMID 22798288 · Dahlman et al., 2012 · Open in CIViC | civic |
| BRAF L597Q1 | ||||||||
| Trametinib + VemurafenibSubstitutes | Cutaneous MelanomaALIAS | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID1461Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutant–expressing cells led… (full text at CIViC) PMID 22798288 · Dahlman et al., 2012 · Open in CIViC | civic |
| BRAF L597R1 | ||||||||
| Trametinib + VemurafenibSubstitutes | Cutaneous MelanomaALIAS | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID1458Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutant–expressing cells led… (full text at CIViC) PMID 22798288 · Dahlman et al., 2012 · Open in CIViC | civic |
| BRAF L597S2 | ||||||||
| MEK Inhibitor REC-4881 | Cutaneous MelanomaALIAS | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID1460Case report of a 69 year old patient with metastatic melanoma treated with MEK inhibitor TAK-733 in a clinical trial. A partial radiographic response with a decrease of 31% in the sum of maximum diame… (full text at CIViC) PMID 22798288 · Dahlman et al., 2012 · Open in CIViC | civic |
| Trametinib + VemurafenibSubstitutes | Cutaneous MelanomaALIAS | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID1459Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutant–expressing cells led… (full text at CIViC) PMID 22798288 · Dahlman et al., 2012 · Open in CIViC | civic |